Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Journal of Patient-Reported Outcomes
|
July 24, 2023
Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron
Manuela Di Fusco, Xiaowu Sun, Mary M Moran, et al.
Infection Control and Hospital Epidemiology
|
September 14, 2022
Determinates of <i>Clostridioides difficile</i> infection (CDI) testing practices among inpatients with diarrhea at selected acute-care hospitals in Rochester, New York, and Atlanta, Georgia, 2020-2021
Scott K Fridkin, Udodirim N Onwubiko, William Dube, et al.
JAMA Network Open
|
December 14, 2022
Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age
Farid L Khan, Jennifer L Nguyen, Tanya G Singh, et al.
The Lancet. Infectious Diseases
|
October 28, 2022
BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
Sara Y Tartof, Jeff M Slezak, Laura Puzniak, et al.
JAMA Network Open
|
December 12, 2024
BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age
Sara Y Tartof, Timothy B Frankland, Laura Puzniak, et al.
Open Forum Infectious Diseases
|
February 12, 2024
Oral COVID-19 Antiviral Uptake Among a Highly Vaccinated US Cohort of Adults With SARS-CoV-2 Infection Between December 2021 and October 2022
Yanhan Shen, McKaylee M Robertson, Sarah G Kulkarni, et al.
JAMA Network Open
|
January 20, 2023
Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System
Sara Y Tartof, Jeff M Slezak, Laura Puzniak, et al.
The Lancet. Respiratory Medicine
|
October 28, 2023
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study
Sara Y Tartof, Jeff M Slezak, Laura Puzniak, et al.
Lancet (London, England)
|
October 7, 2021
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Sara Y Tartof, Jeff M Slezak, Heidi Fischer, et al.
Lancet Regional Health. Americas
|
February 21, 2022
Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study
Sara Y Tartof, Jeff M Slezak, Laura Puzniak, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Journal of Patient-Reported Outcomes
|
July 24, 2023
Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron
Manuela Di Fusco, Xiaowu Sun, Mary M Moran, et al.
Infection Control and Hospital Epidemiology
|
September 14, 2022
Determinates of <i>Clostridioides difficile</i> infection (CDI) testing practices among inpatients with diarrhea at selected acute-care hospitals in Rochester, New York, and Atlanta, Georgia, 2020-2021
Scott K Fridkin, Udodirim N Onwubiko, William Dube, et al.
JAMA Network Open
|
December 14, 2022
Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age
Farid L Khan, Jennifer L Nguyen, Tanya G Singh, et al.
The Lancet. Infectious Diseases
|
October 28, 2022
BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
Sara Y Tartof, Jeff M Slezak, Laura Puzniak, et al.
JAMA Network Open
|
December 12, 2024
BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age
Sara Y Tartof, Timothy B Frankland, Laura Puzniak, et al.
Open Forum Infectious Diseases
|
February 12, 2024
Oral COVID-19 Antiviral Uptake Among a Highly Vaccinated US Cohort of Adults With SARS-CoV-2 Infection Between December 2021 and October 2022
Yanhan Shen, McKaylee M Robertson, Sarah G Kulkarni, et al.
JAMA Network Open
|
January 20, 2023
Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System
Sara Y Tartof, Jeff M Slezak, Laura Puzniak, et al.
The Lancet. Respiratory Medicine
|
October 28, 2023
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study
Sara Y Tartof, Jeff M Slezak, Laura Puzniak, et al.
Lancet (London, England)
|
October 7, 2021
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Sara Y Tartof, Jeff M Slezak, Heidi Fischer, et al.
Lancet Regional Health. Americas
|
February 21, 2022
Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study
Sara Y Tartof, Jeff M Slezak, Laura Puzniak, et al.
Page
of 3